桑蝶 , 王佳玉 , 徐兵河 . 增殖细胞核抗原Ki67 与乳腺癌新辅助化疗疗效的关系[J]. 中华乳腺病杂志(电子版), 2015 , 09(01) : 50 -53 . DOI: 10.3877/cma. j. issn.1674-0807.2015.01.011

[1]	Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CA Cance J Clin,2011,61(2): 69-90.

[2]	郑莹,吴春晓,吴凡. 中国女性乳腺癌死亡现状和发展趋势[J].中华预防医学杂志,2011,45(2): 150-154.

[3]	Yerushalmi R,Woods R,Ravdin PM,et al. Ki67 in breast cancer: prognostic and predictive potential[J]. Lancet Oncol,2010,11(2): 174-183.

[4]	Gerdes J,Schwab U,Lemke H,et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation [J]. Int J Cancer,1983,31(1): 13-20.

[5]	Gerdes J,Lemke H,Baisch H,et al.Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki67[J]. J Immunol,1984,133 (4): 1710-1715.

[6]	MacCallum DE,Hall PA. The location of pKi67 in the outer dense fibrillary compartment of the nucleolus points to a role in ribosome biogenesis during the cell division cycle[J].J Pathol,2000,190(5): 537-544.

[7]	Cheang MC,Chia SK,Voduc D,et al. Ki67 index,HER2 status,and prognosis of patients with luminal B breast cancer[J].J Natl Cancer Inst,2009,101(10): 736-750.

[8]	曹丹霞,何建蓉,沈坤炜,等.激素受体和HER-2 及Ki-67 预测乳腺癌新辅助化疗疗效价值的分析[J].中华肿瘤防治杂志,2012,19(13): 1000-1003.

[9]	Bear HD,Anderson S,Brown A,et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27[J]. J Clin Oncol,2003,21(22): 4165-4174.

[10]	黄朝光,辛付莹.乳腺癌P53、Ki-67 表达与新辅助化疗疗效的相关性研究[J]. 中国社区医师(医学专业),2011,13(271): 260.

[11]	黄宇,胡晓桦,刘志辉.Ki-67 表达与鼻咽癌、乳腺癌化疗疗效及预后的临床分析[J/CD].中华临床医师杂志: 电子版,2013,7(2): 641-645.

[12]	张云好,陈天文,王开昕,等.Ki67 表达在乳腺癌新辅助化疗中的临床意义[J].实用医院临床杂志2012,9(4): 60-62.

[13]	Nishimura R,Osako,Okumura Y,et al. Clinical significance of Ki67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis [J]. Breast Cancer,2010,17 (4): 269-275.

[14]	Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St.gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 [J]. Ann Oncol,2011,22(8): 1736-1747.

[15]	de Azambuja E,Cardoso F,de Castro G Jr,et al. Ki67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients [J]. Br J Cancer,2007,96(10): 1504-1513.

[16]	Von minckwitz G,Schmitt WD,Loibl S,et al. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer [J].Clin Cancer Res,2013,19(16): 4521-4531.

[17]

Ohno S, Chow LW, Sato N, et al. Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide(FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy[J].Breast Cancer Res Treat,2013,142(1): 69-80.

[18]	Yoshioka T, Hosoda M, Yamamoto M, et al. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer[J].Breast Cancer,2015,22(2): 185-191.

[19]	程岩,徐玲,刘倩,等.乳腺癌新辅助治疗疗效相关因素分析[J].中国实用外科杂志,2012,32(11): 950-952.

[20]	Denkert C,Loibl S,Müller BM,et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial[J].Ann Oncol,2013,24(11): 2786-2793.

[21]	Sueta A,Yamamoto Y,Hayashi M,et al.Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes? [J].Surgery,2014,155(5): 927-935.

[22]	马祥君,何湘萍,汪洁,等. 乳腺癌新辅助化疗后不同时间Ki-67 变化规律研究[J]. 中华肿瘤防治杂志,2010,17(13): 976-978.

[23]

Citron ML,Berry DA,Cirrincione C,et al. Randomized trial of dose-dense versus Conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trail 9741[J].J Clin Oncol,2003,21(8): 1431-1439.

[24]	Dent R,Trudeau M,Pritchard KI,et al. Triple-negative breast cancer: clinical features and patterns of recurrence[J]. Clin Cancer Res,2007,13(15 pt 1): 4429-4434.

[25]	Liedtke C,Mazouni C,Hess KR,et al.Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer [J].J Clin Oncol,2008,26(8): 1275-1281.

[26]	Colleoni M,Viale G,Zahrieh D,et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment[J]. Clin Cancer Res,2004,10(19): 6622-6628.

[27]	Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer [J]. J Clin Oncol,2010,28(7): 1145-1153.

[28]	叶国麟,杨劼,古卫权,等.Ki-67 表达对“三阴性”乳腺癌新辅助化疗疗效影响[J].河北医学,2013,19(6): 832-834.

[29]	戴文斌,黄平,任占平,等. MCM7 和Ki-67 在乳腺癌中的表达及其与新辅助化疗关系的研究[J].实用肿瘤杂志,2010,25(1): 20-23.

[30]	朱伟良,谈炎,王旭芬,等. Ki-67 在乳腺癌各亚型中的表达及意义[J].中国癌症杂志,2012,22(5): 347-351.

[31]	王永南,王颀,张安泰,等. Ki-67 与分子亚型预测乳腺癌新辅助化疗敏感性的研究[J]. 中华肿瘤防治杂志,2012,19(23): 1805-1809.

[32]	von Minckwitz G,Sinn HP,Raab G,et al.Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast [J].Breast Cancer Res,2008,10(2): R30.

[33]	Wang J,Xu B,Yuan P,et al. TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy [J]. Breast Cancer Res Treat,2012,135(2): 531-537.

[34]	Jones RL,Salter J,A’Hern R,et al.The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer[J].Breast Cancer Res Treat,2009,116(1): 53-68.

[35]	Jacquemier J,Charafe-Jauffret E,Monville F,et al. Association of GATA3,P53,Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer [J]. Breast Cancer Res,2009,11(2): R23.

[36]	Ahlin C, Fernö M,Amini RM,et al. Ki67 and cyclin Aprognostic factors in breast cancer. Time to introduce proliferation markers in clinical routine [J]. Lakartidningen,2010,107(10): 672-675.

[37]	Werynska B,Pula B,Muszczynska-Bernhard B,et al.Correlation between expression of metallothionein and expression of Ki67 and MCM-2 proliferation markers in non-small cell lung cancer[J].Anticancer Res,2011,31(9): 2833-2839.

[38]	Sole CV, Calvo FA. Research opportunities for vascular endothelial growth factor receptor and Ki67 relative percentage co-reduction in patients with locally advanced rectal cancer treated with neoadjuvant therapy [J]. Clin Oncol, 2014,26(2): 122-123.